BIORA THERAPEUTICS INC (BIOR)

BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q1 2024

BIOR stock results show that Biora Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biora Therapeutics (NASDAQ:BIOR) just reported results for the first quarter of...

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Management will host conference call and webcast today, May 15, 2024, at 4:30 PM Eastern / 1:30 PM Pacific....

Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update

Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update

The company’s management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets....

Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024

Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600

Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology

Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development

All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed...

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery,...

Biora Therapeutics Announces $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BIOR Stock Earnings: Biora Therapeutics Misses EPS for Q4 2023

BIOR stock results show that Biora Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

BIOR Stock Earnings: Biora Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biora Therapeutics (NASDAQ:BIOR) just reported results for the fourth quarter o...

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

Biora Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

Biora Therapeutics Further Reduces Net Debt and Monetizes Legacy Asset

Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600

Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium

Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium

Dr. Ariella Kelman to participate in panel titled

Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.

Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.

Biora will participate in a virtual fireside chat hosted by H.C. Wainwright & Co. on Monday, January 29, 2024 at 11:00 AM Eastern / 8:00 AM Pacific....

Biora Therapeutics Provides Outlook for 2024

Multiple catalysts anticipated in 2024, including clinical study results for NaviCap™ Targeted Oral Delivery Platform and progress on pharma partnerships for BioJet™ Systemic Oral Delivery Platform

Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600

Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600

SAD/MAD study to evaluate safety and PK/PD of BT-600 drug-device combination, including concentrations in colon tissue ...